Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Tablets, lozenges, or pills

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424400000 - PREPARATIONS CHARACTERIZED BY SPECIAL PHYSICAL FORM

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424465000 With claimed perfecting feature in contents (e.g., excipient, lubricant, etc.) 360
424474000 Coated pills or tablets 331
424468000 Sustained or differential release type 258
424467000 Printed, embossed, grooved, or perforated 21
424466000 Effervescent 17
Entries
DocumentTitleDate
20120201880CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.08-09-2012
20090123538Angiotensin II Receptor Antagonists - The compounds of the present invention are polymorphic crystalline forms of the compound 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid, which has the structure (I). Specifically, the compounds of the invention are selected from the group consisting of 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid of Claim 05-14-2009
20090123539WET GRANULATION USING A WATER SEQUESTERING AGENT - Disclosed are tablets comprising hydrolytically stable formulations of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt (Compound 1) prepared by a wet granulation process.05-14-2009
20090136569Rapidly disintergrating tablet in oral cavity - The present invention provides a method of suppressing the bitter taste of a drug when a rapidly disintegrating tablet in an oral cavity is produced.05-28-2009
20110182987PHARMACEUTICAL DOSAGE FORM FOR THE SITE-SPECIFIC DELIVERY OF MORE THAN ONE ACTIVE PHARMACEUTICAL INGREDIENT - This invention relates to a pharmaceutical dosage form for the site specific delivery of more than one active pharmaceutical ingredient to different sites in the human or animal body in the gastrointestinal tract. The dosage form has an outer polymeric layer incorporating a first active pharmaceutical ingredient which reacts to stimuli specific in the stomach, degrades, and releases the first active pharmaceutical ingredient in the stomach for absorption. The dosage form also has at least one inner polymeric layer incorporating a second active pharmaceutical ingredient which, once the outer layer has degraded, passes into the intestine where the polymers of the second layer degrade to release the second active pharmaceutical ingredient. The dosage form may have additional layers each incorporating active pharmaceutical ingredients for release in different portions of the intestine depending on the nature of the polymers.07-28-2011
20100062061Method For Making Cetirizine Tablets - In one aspect, the present invention features a method of producing a tablet including cetirizine including the steps of: (i) mixing cetirizine, a polyol, and a solvent for the cetirizine to form a cetirizine:polyol complex, wherein the solvent comprises water and an alkalizing agent and has a pH from about 2 to about 7; (ii) isolating particles of the cetirizine:polyol complex from the mixture; and (iii) forming the particles into a tablet.03-11-2010
20100021540Tablets and Preparation Thereof - The present invention features processes of making tablets having reduced internal fractures. In one aspect, the processes comprise the steps of (1) compressing a pre-tabletting material in a die to form a tablet, where an internal surface of the die is lubricated with at least one lubricant and the pre-tabletting material comprises at least one therapeutic agent and at least one pharmaceutically acceptable polymer; and (2) ejecting said tablet from said die. In another aspect, the processes employ a granular or powdery pre-tabletting material which comprises at least one therapeutic agent and at least one pharmaceutically acceptable polymer, wherein 90% of the particles in the pre-tabletting material are smaller than 400 μm.01-28-2010
20080260823ORALLY DISINTEGRATING TABLET COMPRISING GLYCOPYRROLATE FOR TREATING SIALORRHEA - The invention provides an orally disintegrating tablet comprising a therapeutically effective amount of glycopyrrolate for treating sialorrhea, as well as a kit comprising the orally disintegrating tablet, prescribing information, and a container. The invention also provides a method of treating sialorrhea in a patient comprising administering the orally disintegrating tablet comprising a therapeutically effective amount of glycopyrrolate to the patient.10-23-2008
20130084332TASTE MASKED PHARMACEUTICAL COMPOSITION - This application relates to taste masked multi-layered particles an inert core, one or more coating layer(s) comprising a pharmaceutically active ingredient and a binder, an intermediate coating layer (seal coating) free from a low molecular weight water-soluble ionic compound and comprising a water-soluble pharmaceutical film-forming compound selected from (i) HPMC and PEG or (ii) PVP, and an outer coating layer (final or taste masking coating) free from a low molecular weight water-soluble ionic compound and comprising (i) a poly(meth)acrylate or (ii) a mixture comprising 60-90% (w/w) EC and 10-40% (w/w) HPMC, wherein the pharmaceutically active ingredient is water-soluble and comprises either at least one basic group and/or a bitter taste. Further disclosed are methods for the production of such particles and pharmaceutical compositions comprising them.04-04-2013
20110262536METHOD TO AUTHENTICATE GENUINE TABLETS MANUFACTURED BY COMPRESSING POWDER - A method to authenticate genuine tablets manufactured by compressing powder between a punch/die set comprising the steps of: creating a microstructure on the surface of at least one of the face of the punch/die set; compressing the powder between the punch and the die; acquiring at least one reference image of the face of the punch/die set containing the microstructure or of a face of a tablet corresponding to the microstructure; acquiring at least one test image of a tablet to be authenticated; computing a level of similarity by an electronic device between the at least one test image and the at least one reference image; comparing the computed level with a threshold value so as to define if the acquired tablet is genuine.10-27-2011
20130039981Quick Dissolving, Long Acting Zinc Therapeutic Formulations - The present invention comprises a quick dissolving, long acting zinc therapeutic cold formulation containing high levels of an active compound encapsulated within bioadhesive/muco-adhesive polymers as a controlled release oral drug delivery system. The composition allows for increased residence time for enhanced prophylactic and therapeutic efficacy within the mouth and oral cavity. This allows for a reduction in the number of doses necessary to achieve therapeutic relief which will result in increased patience compliance.02-14-2013
20090155359GRANULATED PARTICLES, TABLETS AND METHOD FOR PRODUCING GRANULATED PARTICLES - The present invention relates to granulated particles including a poorly water soluble drug (A) and a diluent (B) and characterized in that a volume average particle size of the particles of the poorly water soluble drug (A) and the particles of the diluent (B) is within the range of 0.01 to 35 μm and a water soluble- or water swellable polymer compound (C) having a viscosity of less than 6.0 mPa·s in an aqueous solution thereof of 2% by mass at 20° C. is further contained, a tablet containing the granulated particles, and a method for producing the granulated particles.06-18-2009
20100104635PROCESS FOR PREPARING GRANULES OF HYDROPHILIC VITAMINS - The present invention relates to a process for preparing granules of a hydrophilic vitamin with polyvinylpyrrolidone as binder in a fluidized bed granulator, to the granules of a hydrophilic vitamin obtained by said process, to tablets made with said granules of a hydrophilic vitamin, to mixture of L-ascorbic acid for direct tabletting and tablets made with said mixtures.04-29-2010
20130028970Tamper-resistant tablet providing immediate drug release - The invention relates to a tamper-resistant tablet comprising 01-31-2013
20100068268STARCH-BASED MICROPARTICLES FOR THE RELEASE OF AGENTS DISPOSED THEREIN - The invention provides starch-based microparticles with high loading capacity for the stabilization and/or controlled release of one or more agents, for example, a pharmaceutical, a taste masking agent, a flavoring agent, or a combination thereof, disposed within the microparticles, and to methods of making and using such microparticles.03-18-2010
20130089607ONCE DAILY TROSPIUM CHLORIDE TREATMENT METHOD - A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (C04-11-2013
20110002987Nicorandil Carriers with Enhanced Stability - The invention provides a carrier for nicorandil, which is preferably in form of a blister pack, comprising one or several dose blister pockets each containing at least one tablet of nicorandil, and at least one blister pocket containing a molecular sieve.01-06-2011
20130071475Method For Producing An Oral Pharmaceutical Form With Immediate Disintegration And Active Ingredient Release - The invention relates to a method for producing an oral form of administration which decomposes immediately and releases active ingredients in the mouth. According to said method, (a) an anionic pharmaceutical active ingredient is intensively mixed with (b) a copolymer consisting of radically polymerized C03-21-2013
20130059002PHARMACEUTICAL COMPOSITIONS COMPRISING A COMBINATION OF METFORMIN AND SITAGLIPTIN - The present invention relates to a pharmaceutical composition, preferably a pharmaceutical dosage form, comprising at least two separate compartments, wherein one compartment contains a composition comprising metformin or a pharmaceutically acceptable salt thereof and wherein another compartment contains a composition comprising sitagliptin.03-07-2013
20090311319Oral Preparation With Controlled Release - Abstract Oral preparation with controlled release A pharmaceutical pellet is provided, comprising a spherical core containing the active substance with a smooth surface and a coating on the core, which controls pH-independent release of the active substance. With a pellet of this kind, the release of the active substance may follow a profile with a lag-phase from 60 minutes to 840 minutes, where during the lag-phase a proportion of 5 wt. % or less of the active substance is released. Furthermore, the active substance may be released from the pellet with a profile such that, after the lag-phase, the release of the active substance is between and 25 wt. % per hour. The active substance is a metoprolol salt.12-17-2009
20130064886Microtablets for Drug Delivery - Methods and systems are provided for making a drug microtablet. The method includes loading a lyophilization capillary channel with a liquid drug solution; lyophilizing the liquid drug solution in the lyophilization capillary channel to produce a lyophilized drug formulation; compressing the lyophilized drug formulation in the lyophilization capillary channel, or in a compression capillary channel, to form a microtablet; and ejecting the microtablet from the lyophilization capillary channel or compression capillary channel. The methods and systems may provide drug microtablets having improved content uniformity and reduced weight variability.03-14-2013
20110020444ABUSE-RESISTANT OPIOID DOSAGE FORM - We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.01-27-2011
20110020443SLOW RELEASE MAGNESIUM COMPOSITION AND USES THEREOF - The present invention provides compositions that contain magnesium and threonate, or a threonate precursor molecule, formulated for extended or modified release to provide physiological concentrations over a desired time period. The extended release or modified release form is particularly useful in providing Mg to a subject while avoiding adverse side effects such as diarrhea.01-27-2011
20090047343Method for stabilizing phenylephrine - The present invention relates to a process for stabilizing phenylephrine including drying an acidic solution of phenylephrine and pharmaceutical compositions including stabilized phenylephrine.02-19-2009
20090011013Tacrolimus Combination Products - The present invention relates to a pharmaceutical composition comprising tacrolimus or an analogue thereof and a substance being a substrate for CYP3A4 and/or P-glycoprotein, oral solid dosage forms comprising the pharmaceutical composition such as tablets, methods for preparing the pharmaceutical composition and oral dosage forms and use of the pharmaceutical composition for preparing a medicament. The substance being a substrate for CYP3A4 and/or P-glycoprotein is preferably cyclosporine A. The invention further relates to treatment of a patient in need thereof by coadministration of the combination according to the invention. In a further aspect, the invention relates to the above combination further comprising a CYP3A4 inhibitor compound, preferably a compound naturally occurring in citrus juice, for example grapefruit juice, preferably a spiro ortho ester compound.01-08-2009
20090117181Tablet comprising fluvastatin and carmellose calcium - The present invention relates to a fluvastatin-containing tablet, particularly a fluvastatin-containing tablet which has excellent disintegrating property and good bioavailability.05-07-2009
20120040000PEPTIDE PHARMACEUTICAL FOR ORAL DELIVERY - Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.02-16-2012
20100028425PHARMACEUTICAL COMPOSITION OF ATOVAQUONE - The present invention relates to immediate release pharmaceutical compositions for oral administration comprising micronized atovaquone particles and at least one drug, wherein about 90% of the atovaquone particles have a volume diameter between about 4 μm to about 8 μm; and having a uniform release profile after a storage for at least three months at 40° C. and 75% relative humidity.02-04-2010
20110008428SOLID PHARMACEUTICAL COMPOSITION COMPRISING A NON-PEPTIDE ANGIOTENSIN II RECEPTOR ANTAGONIST AND A DIURETIC - The present invention relates to a solid pharmaceutical composition comprising at least two layers, wherein the first layer contains a non-peptide angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof in a dissolving matrix and the second layer contains a diuretic or a pharmaceutically acceptable salt thereof. The invention also provides methods for the production of said pharmaceutical compositions.01-13-2011
20090028936Tablets containing enrofloxacin and flavouring agents and/or flavours - The present invention relates to tablets for animals, which tablets comprise enrofloxacin as well as flavourings and/or aromatizing substances.01-29-2009
20080279932Compounds - The present invention relates to novel salt forms of vildagliptin (LAF237), i.e. salt forms of(S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine.11-13-2008
20080279933FLURBIPROFEN AND MUSCLE RELAXANT COMBINATIONS - This invention is a novel pharmaceutical composition comprising flurbiprofen or a pharmaceutically acceptable salt thereof in combination with an α-2 adrenergic receptor agonist or a gamma-aminobutiric acid receptor agonist with anti-inflammatory, analgesic and myorelaxant activity.11-13-2008
20120231076PHARMACEUTICAL COMPOSITIONS COMPRISING RIVAROXABAN - The invention relates to pharmaceutical compositions comprising rivaroxaban, suitable for immediate release, and processes of preparing such compositions, preferably by a melt-granulation process or by a specific direct-compression process.09-13-2012
20090252791PHARMACEUTICAL COMPOSITIONS COMPRISING A TRIPTAN AND A NONSTEROIDAL ANTI-INFLAMMATORY DRUG - Dosage forms for administering a triptan and a nonsteroidal anti-inflammatory drug are disclosed, including multilayered tablets and mini-tablets. These multilayered tablets can be in a side-by-side arrangement, can be inlayed, or one layer can completely surround another. These can be administered in a capsule or directly. Other formulations are also disclosed.10-08-2009
20090324713SPRAY-ON, NON-WOVEN FABRIC SYSTEM AND MULTILAYER WOUND COVERINGS - The invention is directed to a spray-on, non-woven fabric system and multilayer wound coverings for promoting wound healing, where the fabric system includes a first spray-on composition including a non-volatile carrier for keeping the wound moist and a second spray-on composition for covering the first composition and protecting the wound which includes fibers, a volatile carrier, and a binding agent, and where the multilayer wound covering includes a first layer formed from the first spray-on composition and a second layer covering the first layer, the second layer formed from the second spray-on composition.12-31-2009
20090142393Stable Compositions of Famotidine and Ibuprofen - Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.06-04-2009
20100330174BETAINE COMPOSITIONS - The invention refers to the pharmaceutical combination including at least: a first compound selected among the group consisting of acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of Formula (CH12-30-2010
20090202630ORALLY DISINTEGRATING TABLET COMPOSITIONS OF RANITIDINE AND METHODS OF MANUFACTURE - The present invention is directed to pharmaceutical compositions comprising taste-masked microcapsules comprising ranitidine, orally disintegrating tablets comprising such compositions, and methods of making the pharmaceutical compositions and dosage forms of the present invention. The present invention is also directed to methods of administering the pharmaceutical compositions and orally disintegrating tablets to treat or prevent gastrointestinal disorders.08-13-2009
20090104262Chlorthalidone combinations - The invention relates to favourable combinations of the thiazide diuretic chlorthalidone with Angiotensin II Receptor Blockers (ARBs) for the treatment of hypertension. 04-23-2009
20100021539Modified Release 1-[(3-Hydroxy-Adamant-1-Ylamino)-Acetyl]-Pyrrolidine-2(S)-Carbonitrile Formulation - The subject invention provides a pharmaceutical tablet formulation comprising per unit dosage form e.g. per tablet the following ingredients: 01-28-2010
20080299191Fine-Particle Crosslinked Polyvinylpyrrolidone as Tablet Disintegrant - Use of crosslinked polyvinylpyrrolidone with an average particle size of 5-60 μm and a hydration capacity of greater than 7 g/g as tablet disintegrant12-04-2008
200901042635-HT4 partial agonist pharmaceutical compositions - A solid pharmaceutical composition for oral administration comprising tegaserod in base or salt form in an amount of up to 10% by weight a bulking agent in an amount of 70 to 90% by weight a disintegrant in an amount of less than 15% by weight a glidant and a lubricant,04-23-2009
20100330173COMPOUNDS AND METHODS FOR TREATING INFLUENZA - This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents.12-30-2010
20090155360ORALLY DISINTEGRATING TABLETS COMPRISING DIPHENHYDRAMINE - The compositions of the present invention comprise a therapeutically effective amount of particles consisting of diphenhydramine or pharmaceutically acceptable salts thereof, optionally in combination with another drug such as pseudoephedrine, or phenylephrine and hydrocodone, in combination with rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol and/or a saccharide. These compositions are useful in treating the symptoms of one or more diseases or conditions in which diphenhydramine (alone or in combination with one or two other drugs) is a therapeutically effective, e.g. allergic rhinitis, sinusitis, upper respiratory tract infections, motion sickness, Parkinson's disease, insomnia, the common cold, and nighttime pain management, particularly for subjects or patients with dysphagia, and people ‘on the move’.06-18-2009
20110217372Fast dissolving oral tablets and method for production thereof - Provided is a fast dissolving oral tablet, and a method for the production thereof, including the steps of: compressing a mixture of active ingredients, pharmaceutically acceptable additives, and supercritical fluid-soluble substances to produce the tablets; and allowing the tablets to contact a supercritical fluid to extract supercritical fluid-soluble substances from fine pores in the tablets.09-08-2011
20090148521SOLID ORAL FORM OF A MEDICINAL PREPARATION AND A METHOD FOR THE PRODUCTION THEREOF - A solid oral form of an antibody-based medicinal preparation comprises an effective carrier quantity irrigated with an active form of an antibody aqueous-alcoholic dilution, which is prepared by combining a repeated successive antibody dilution with an external action, and pharmaceutically acceptable additives. The inventive method for producing a solid oral form of the antibody-based medicinal preparation consists in preparing an aqueous-alcoholic dilution of anti-substance antibodies, obtaining the active form by combining a repeated successive dilution and an external action according to a homeopathic process, irrigating a carrier with the thus obtained aqueous-alcoholic dilution in a fluidized boiling bed with concurrent drying of said carrier at a temperature equal to OT less than 35° C., mixing in a pharmaceutically acceptable sequence with pharmaceutically acceptable additives and in subsequent pelletization—forming tablets by means of a direct dry pressing.06-11-2009
20110091545Direct Injection moldable and rapidly disintegrating tablet matrix - The present invention relates to a novel directly compressible matrix for the production of tablets which disintegrate rapidly in the presence of moisture, in particular in the mouth.04-21-2011
20100086590NOVEL STABLE PHARMACEUTICAL COMPOSITIONS OF CLOPIDOGREL BISULFATE AND PROCESS OF PREPARATION THEREOF - The present invention discloses novel stable oral pharmaceutical compositions comprising the active ingredient Clopidogrel bisulfate and hydrophilic polymers along with pharmaceutically acceptable excipients. Particularly, the said Clopidogrel bisulfate is crystalline Form 1 and the composition additionally comprises of one or more chelating agents and antioxidants. Further the invention relates to a novel process for preparation of stable pharmaceutical compositions wherein the Clopidogrel bisulfate Form I is coated with a hydrophilic polymer thereby providing an increased physical and chemical stability to the composition.04-08-2010
20090304790CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.12-10-2009
20120034301TABLET AND PESTLE THEREFOR - A tablet which comprises solid particles, especially magnesium oxide particles as the main component and has excellent shape retentivity with extremely low susceptibility to wearing and chipping. The tablet has a domed shape on each of the upper and lower horizontal surfaces of a cylindrical plate shape, wherein the domed shape on each of the upper and lower horizontal surfaces satisfies the following requirements (a), (b) and (c) in the cross-sectional shape including the center line of the cylindrical plate shape: (a) each corner has an angle of 25 to 45°, (b) each corner has a horizontal length of 0.30 to 1.0 mm, and (c) the cup has a depth of 0.6 to 1.2 mm.02-09-2012
20100119601MELATONIN TABLET AND METHODS OF PREPARATION AND USE - The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the indole hormone melatonin, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition.05-13-2010
20100080847MEDICINAL COMPOSITIONS QUICKLY DISINTEGRATING IN THE ORAL CAVITY AND PROCESS FOR PRODUCING THE SAME - This invention relates to a medicinal composition, which rapidly disintegrates when taken in the oral cavity and shows sufficient hardness upon production, distribution and use in usual manner, can be obtained by adding, to a sugar alcohol and/or saccharide, a sugar alcohol and/or saccharide having a lower melting point than the first-mentioned sugar alcohol and/or saccharide and then subjecting the resulting powder to combined processing of compression and heating. This invention can provide medicinal compositions, which rapidly disintegrate when taken in the oral cavity without water and are excellent in handling ease owing to exhibition of sufficient hardness upon their production, transportation and use in usual manner, and can also provide a process for the production of the medicinal compositions, which is simpler and can avoid contact between an active ingredient and water as needed.04-01-2010
20090087485Orally Disintegrating Tablets - The present invention describes a directly compressible composite excipient prepared by coating calcium silicate with a carbohydrate. The present invention further describes the incorporation of the composite excipient into a tablet formulation. The orally disintegrating tablets are of optimal mechanical strength and disintegrate within 60 seconds in the oral cavity.04-02-2009
20090291135Direct compression polymer tablet core - The present invention provides a tablet core which comprises at least about 95% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 95% by weight of an aliphatic amine polymer resin The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 95% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating.11-26-2009
20120107397PHARMACEUTICAL COMPOSITIONS OF VALSARTAN - The present invention relates to the stable pharmaceutical composition comprising valsartan or a pharmaceutically acceptable salt thereof with mannitol as a filler and povidone as binder. The present invention also relate to the valsartan or pharmaceutically acceptable salt thereof in combination with hydrochlorothiazide or amlodipine or both; and optionally one or more additional excipients.05-03-2012
20120107396Compositions For The Treatment of Central Nervous System Disorders Including Depression Employing Novel Drug Combination Therapy To Reduce Suicidality In Patients - Described herein are novel methods and formulations for reducing suicidality in human subjects. Such formulations and methods are a combination of lithium and one or more other CNS therapeutic agents such as anti-depressant, mood-stabilizing, anxiolytic, anticonvulsant, antipsychotic, anti-addictive, and appetite suppressant drugs.05-03-2012
20100098755PROCESS OF PRODUCING DIRECTLY COMPRESSED TABLETS OF STEROLS AND/OR STANOLS - A method of producing a tablet which comprises sterols and stanols includes the steps of forming the sterols and/or stanols, separately or together, into spherically-shaped, substantially uniform beads or prills and directly compressing the beads or prills into a tablet core.04-22-2010
20090047344Formulations - The present invention relates to pharmaceutical compositions for oral administration of active compounds.02-19-2009
20080206327SOLID DOSAGE FORMULATIONS CONTAINING WEIGHT-LOSS DRUGS - An orally disintegrating tablet which can be chewed or disintegrated by contact with saliva and containing weight-loss drugs for weight control in humans, especially in children and adolescents, is disclosed.08-28-2008
20080206326Production Process For Nsaid-Containing Lozenges, Their Compositions, Their Medicinal Use - A process for producing a pharmaceutical lozenge formulation comprising the steps of: (a) providing a liquid composition comprising a salt of a non-steroidal anti-inflammatory drug (NSAID salt) and a solvent system, (b) providing a molten lozenge-forming composition, (c) mixing the liquid composition with the molten lozenge-forming composition, and, (d) forming the resulting mixture into lozenges each containing a therapeutically effective amount of said NSAID salt/NSAID mixture. The present application discloses the corresponding NSAID-containing lozenge compositions and their use for the manufacture of a medicament for treating sore throat.08-28-2008
20090142392Composition Comprising a NSAID and Paracetamol - A process for producing a granular composition comprising a plurality of solidified melt granules including a non-steroidal anti-inflammatory drug (NSAID) and paracetamol (acetaminophen), the process comprising the steps of: (a) forming a melt mixture by mixing a molten NSAID free acid and paracetamol, optionally with one or more excipients; and (b) forming the melt mixture into solidified melt granules. The granules are useable in compositions for treating pain and/or inflammation and/or fever.06-04-2009
20100291206ORAL DOSAGE FORM - A pharmaceutical or nutraceutical tablet for oral administration comprising at least two fatty acids or derivatives thereof and cyclodextrin. Surprisingly, we have now found that fatty acids or derivatives thereof, especially fatty acid esters, preferably in the form of complexes with cyclodextrins prepared as stable solid materials, can easily be transformed into tablets with very high concentration of the fatty acid compound. The present inventors have realised that ideal dosage forms for these compounds are tablets and these are readily swallowed and are cheap to manufacture. In particular, the inventors have found that tablets containing complexes of fatty acids or derivatives thereof with cyclodextrin can be prepared by direct compression and moreover they can be prepared having a very high concentration of the desired active agent.11-18-2010
20110268796PHARMACEUTICAL FORMULATIONS USEFUL IN THE TREATMENT OF INSOMNIA - There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.11-03-2011
20090169620ORALLY DISINTEGRATING TABLET COMPOSITIONS OF TEMAZEPAM - The compositions of the present invention are orally disintegrating tablet compositions comprising a therapeutically effective amount of at least one drug such as temazepam, 0.5-3% of an ODT binder polymer, a sugar alcohol and/or saccharide, and a disintegrant.07-02-2009
20080213358Method And Device For Ultrasound-Pressing A Tablet Or A Multiparticulate Medicament - The present invention relates to a method and a device for shaping a pharmaceutically active substance in the form of powders, granules, multiparticulate medicaments, in particular pellets and microcapsules, for the production of a tablet or a multiparticulate medicament by means of ultrasound, with an ultrasound generator, a sonotrode and a mould, into which the pharmaceutically active substance can be poured.09-04-2008
20120141585IMMUNOMODULATORY COMPOSITIONS COMPRISING A POLYMER MATRIX AND AN OIL PHASE - A pharmaceutical composition comprising a water-soluble polymer matrix in which are dispersed droplets of oil, the composition comprising at least one immunomodulator selected from an adjuvant, an antigen or a combination thereof. A method of manufacturing shaped compositions comprises mixing an aqueous solution of a water-soluble polymer with an oil-based liquid to form a water-in-oil emulsion, at least one of the aqueous solution and the oil-based liquid comprising an antigen or an adjuvant or a combination thereof, and then causing or allowing the resultant suspension to solidify into one or more beads or other shaped elements06-07-2012
20090028938DOSAGE FORMS WITH IMPROVED BIOAVAILABILITY - A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35>ΔH01-29-2009
20090136568Tabletting process - A process for producing a compressed solid dosage form containing an active ingredient. The process includes a step of preparing core elements containing the active ingredient. Optionally the core elements are coated with a pharmaceutically acceptable coating layer to form coated pellets. The core elements or pellets are treated with an anti-static agent and compressed with suitable excipients to form the compressed solid dosage form. Preferred anti static agents are starch, microcrystalline cellulose, kaolin, bentonite, silicates, silicon dioxide, cellulose, stearic acid, sodium stearyl fumarate and glyceryl behenate.05-28-2009
20080317849Method for Improving the Medical Treatment of Pain - Methods for improving pain management in a mammal, the methods comprising administering a combination of a strontium-containing compound and a second therapeutically and/or prophylactically active substance selected from the group consisting of analgesic agents, anti-inflammatory agents and palliative agents to the mammal. Pharmaceutical compositions for use in such methods, comprising a strontium-containing compound and a second therapeutically and/or prophylactically active substance selected from the group consisting of analgesic agents, anti-inflammatory agents and palliative agents.12-25-2008
20110229567SOLID PHARMACEUTICAL COMPOSITION - The present invention provides a solid preparation containing compound (I) or a salt thereof, a pH control agent and a calcium antagonist, which is superior in the dissolution property, stability and the like.09-22-2011
20090004265Prevention and Treatment of Thromboembolic Disorders - The present invention relates to the field of blood coagulation, more specifically it relates to a method of treating a thromboembolic disorder by administering once daily a direct factor Xa inhibitor in oral dosage form to a patient in need thereof, wherein the factor Xa inhibitor has a plasma concentration half life indicative of a bid or tid administration interval, e.g. of 10 hours or less.01-01-2009
20090252790TABLET FORMULATION - The present invention relates to a pharmaceutical fixed dose combination tablet comprising repaglinide and metformin. The present invention also provides a method of producing said tablet.10-08-2009
20100151016METHOD FOR PRODUCING PHARMACEUTICAL TABLET - A process for advantageously producing tablets having an improved release property and an excellent stability to change with time is provided. The process is for producing tablets containing a morphinan compound represented by the Formula (I) below or pharmaceutically acceptable acid addition salt thereof and an acidic substance such as fumaric acid, maleic acid or adipic acid, and characterized in that the morphinan compound or a pharmaceutically acceptable acid addition salt thereof is granulated by wet granulation together with (an) excipient(s) prior to adding the acidic substance thereto.06-17-2010
20120195965SOLID DOSAGE FORM COMPRISING A FIBRATE - The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.08-02-2012
20090117182INTRAORALLY RAPIDLY DISINTEGRATING TABLET - The present invention provides an intraorally rapidly disintegrating tablet that can be formed using an ordinary apparatus, that has hardness with no practical problem and that disintegrates rapidly with good feeling in the oral cavity.05-07-2009
20100260840Orodispersible pharmaceutical composition of agomelatine - The invention relates to a solid orodispersible pharmaceutical composition of agomelatine, characterised in that it comprises agomelatine and granules consisting of co-dried lactose and starch.10-14-2010
20080268044Novel Process and Formulations - The present invention provides for a novel process of making 6-carboxylic acid derivatives of pyrido[2,3-d]pyrimidin-7-one's, as well as a novel process for making 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-{[2-hydroxy-1-(hydroxymethyl)ethyl]-amino}pyrido[2,3-d]pyrimidin-7(8H)-one, and salts thereof.10-30-2008
20110059170METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS - Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.03-10-2011
20100255089Pharmaceutical Compositions and Methods of Using Same - A pharmaceutical composition is provided that comprises a solid dispersion of implitapide. Such solid dispersions may include implitapide and least one pharmaceutically acceptable excipient. In some embodiments, the disclosed solid dispersions comprise substantially amorphous implitapide.10-07-2010
20100233257LOW DOSE SUBLINGUAL TABLETS OF OPIOID ANALGESICS AND PREPARATION PROCESS - The present invention relates to a sublingual tablet and to the method for the preparation thereof.09-16-2010
20090074860NUTRITIONAL BEVERAGE WITH SKIN IMPROVEMENT AIDS - This invention provides a nutritional beverage solution assistive to the visual appearance of a consumer's skin. In optional preferred embodiments, the solution includes primary antioxidant Vitamins C & E, secondary antioxidant of at least one of a Grape Seed Extract, a Papaya Extract, a Guava Extract, an Acai Extract, a Green Tea Extract, a Chamomile Extract, a Cherimoya Extract, a Longan Extract, a Lychee Extract, a Pomegranate Extract, a Walnut Extract or a Mangosteen Extract, along with a unique combination of other select ingredients to improve the nutritional content, and consumer acceptance of the beverage including taste and color factors. Alternative embodiments may vary the ingredients and may be placed be in a variety of consumer desired forms including paste, powder, gel, or encapsulated in a pill.03-19-2009
20100221332METHODOLOGY AND APPARATUS FOR ORAL DUAL DELIVERY OF HOMEOPATHIC PRODUCTS AND NON-HOMEOPATHIC PRODUCTS - One possible embodiment of the invention may be an oral dosage apparatus comprising of a sealed, digestible container having an exterior that defines and seals a respective interior; the interior containing one or more non-homeopathic remedies; and the exterior presenting one or more homeopathic products. Another version of the invention may be a method of manufacturing an oral dosage apparatus comprising of the following steps of providing one or more non-homeopathic remedies and one or more non-homeopathic remedies; providing a sealed, digestible container having an exterior that correspondingly defines and seals a respective interior containing one or one or more non-homeopathic remedies; affixing one or more homeopathic remedies to the exterior.09-02-2010
20080299192Intraorally Rapidly Disintergrating Tablets and Their Production - The object of the present invention is to provide, as a solid preparation for making it easy to take, thus improving patient's compliance etc., an intraorally rapidly disintegrating tablet which can be produced easily without any particular problem by a usual method of producing tablets with a usual tabletting machine, has practically unproblematic hardness, and disintegrate rapidly in the oral cavity. This tablet is produced by tabletting cores coated with a pharmaceutical disintegrating agent, wherein the core is a granule containing a water-soluble medicament or containing a medicament and a sugar.12-04-2008
20100303906SOLID DOSAGE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD OF MAKING SAME - Monolayer and bilayer solid dosage forms of a combination of valsartan and amlodipine are made.12-02-2010
20130136793High Content Sodium Ibuprofen Granules, Their Preparation and Their Use in Preparing Non-Effervescent Solid Dosage Forms - Disclosed is a method for the preparation of easily-swallowed, reliably-dosed, aesthetically-improved tablets of sodium ibuprofen dihydrate, the method comprising the formation of the tablets with punches or presses comprising contact surfaces which are chrome or chrome-plated.05-30-2013
20090068262Rapid dissolution of combination products - Provided are rapidly dissolving pharmaceutical oral dosage forms of triptans and NSAIDs, processes for the preparation thereof, and methods of treatment therewith.03-12-2009
20100260839AQUEOUS FILM COATING SOLUTION, FILM COATED GRANULE AND TABLET USING THE SAME - An object of the present invention is to provide an aqueous film coating solution, and the like, which has good acid resistance and sustained release properties as well as the flexibility suitable for the tablet compression force and are highly productive and cost efficient. The aqueous film coating solution of the present invention comprises an ethyl acrylate/methyl methacrylate copolymer dispersion, a methacrylic acid copolymer LD, a plasticizer, titanium oxide and water, wherein the solid mass ratio of the ethyl acrylate/methyl methacrylate copolymer dispersion, the methacrylic acid copolymer LD, the plasticizer and the titanium oxide is 100:(40 to 100):(5 to 50):(5 to 30) and the solid content thereof is 5 to 20 mass %.10-14-2010
20110111024PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF A LEVODOPA PRODRUG AND METHODS OF USE - Pharmaceutical compositions and oral dosage forms of (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and methods of treating diseases comprising orally administering such pharmaceutical compositions and dosage forms are disclosed.05-12-2011
20110150993Fine Particle Croscarmellose and Uses Thereof - The disclosure is directed to fine particle croscarmellose and its use in various compositions such as solid dosage forms. More specifically, the present disclosure relates to fine particle croscarmellose having a median particle size of 5 μm to 36 μm and a volume mean diameter of 40 μm or less. The specific surface area is typically 0.3 m06-23-2011
20110244039ABSORBABLE SOLID COMPOSITIONS FOR TOPICAL TREATMENT OF ORAL MUCOSAL DISORDERS - The invention provides a solid, self-bioadhesive composition for topical application that adheres to the oral mucosal tissue comprising a therapeutically effective amount of at least one herbal or homeopathic active agent; and a pharmaceutically acceptable solid bioadhesive carrier in an amount from about 40 to 99 percent based on the weight of the whole composition.10-06-2011
20100221331PHARMACEUTICAL COMPOSITIONS COMPRISING COLLOIDAL SILICON DIOXIDE - The present invention provides a pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide. The composition comprises 1 to 5% colloidal silicon dioxide by weight.09-02-2010
20090028937TABLET COMPRISING ORNITHINE HYDROCHLORIDE - The present invention has an object to provide a tablet capable of comprising ornithine hydrochloride in a higher content; and a process for producing the same, and provides the tablet comprising ornithine hydrochloride and maltose, or a linear or cyclic dextrin; and the process for producing a tablet comprising ornithine hydrochloride, which comprises compression molding a mixture comprising ornithine hydrochloride and maltose, or a linear or cyclic dextrin by a direct tableting method.01-29-2009
20090028939Solid Preparation - The present invention intends to provide a solid preparation which contains an insulin sensitizer and an active ingredient other than an insulin sensitizer, and exhibits dissolution behavior of an insulin sensitizer similar to that of an insulin sensitizer from “a solid preparation containing only an insulin sensitizer as an active ingredient”. The solid preparation comprises “a part containing coated particles in which the particles containing an insulin sensitizer are coated with lactose or a sugar alcohol” and “a part containing an active ingredient other than an insulin sensitizer”.01-29-2009
20110104270PROCESS FOR PRODUCTION OF SPHERICAL MICROPARTICLES COMPRISING TAMSULOSIN HYDROCHLORIDE - The present invention provides a method for producing spherical fine particles containing tamsulosin hydrochloride, the method includes the steps of: (05-05-2011
20110070301ORALLY TRANSFORMABLE TABLETS - The present invention features a tablet including one or more pharmaceutically active agent(s), one or more thickeners, and one or more binder(s), wherein the tablet includes at least 200 mg of the pharmaceutically active agent(s) and the tablet has been fused with the binder(s) such that the tablet (i) has a water permeation time of less than 60 seconds and (ii) has an in vitro disintegration time of greater than 60 seconds.03-24-2011
20120201879CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.08-09-2012
20100303905Orally Disintegrating Tablet Compositions of Lamotrigine - The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.12-02-2010
20120034300STABILIZED ZOLPIDEM PHARMACEUTICAL COMPOSITIONS - Methods of inducing antinociception in a human are described. The method includes the step of administering an effective dose of a polypeptide comprising L-neo-tryptophan to the human extracranially. The polypeptide containing L-neo-tryptophan could be, but is not limited to, NT64L, NT65L, NT66L, NT67L, NT69L, NT69L′, NT71, NT72, NT73, NT74, NT75, NT76, or NT77.02-09-2012
20120201882CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.08-09-2012
20120201878CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.08-09-2012
20120201877Calcium Carbonate Granulation - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.08-09-2012
20110212172ADMINISTRATION OF AN ADSORBENT POLYMER FOR TREATMENT OF SYSTEMIC INFLAMMATION - The invention provides a method of ameliorating systemic inflammation in a patient involving administering to the patient a therapeutically effective dose of composition including polystyrene divinyl benzene copolymer and a polyvinyl pyrrolidone polymer. More particularly, the method relates to using these polymers as an enteral sorbent preparation to remove inflammatory mediators, such as cytokines, from the intestinal lumen. The polymers can be in the form of a preparation of polystyrene divinyl benzene copolymer beads with a biocompatible polyvinyl pyrrolidone polymer coating.09-01-2011
20110159091RAPIDLY DISPERSIBLE VAGINAL TABLET THAT PROVIDES A BIOADHESIVE GEL - A tablet for insertion into a vagina including 0.01 to 500 mg of a vaginal medication, such as a microbicide, such as cellulose acetate 1,2-benzenedicarboxylate (CAP); 100 to 500 mg of mannitol powder; 50 to 300 mg of inert microcrystalline cellulose; 10 to 80 mg of hydroxypropyl methylcellulose; 50 to 250 mg of glycerol and optionally 2 to 4 mg of at least one preservative which protects against microbicidal contamination and discourages the growth of yeast in the vagina. The tablet which includes CAP as the vaginal medication is vaginally administered before coitus in methods for preventing the sexual transmission of HIV-1, HIV-2, herpesvirus, or an infection caused by 06-30-2011
20080305166Robust rapid disintegration tablet formulation - A rapidly disintegrating, orally administered tablet or compressed dosage form, comprising ethylcellulose (EC) as a directly compressible binder which enhances tablet robustness as manifested by improved strength, lower friability, lower hygroscopicity and yet, hydrophobic nature notwithstanding, does not retard disintegration, but shortens disintegration time or is disintegration time neutral when co-formulated with disintegrants and other water-soluble excipients such as sugar alcohols.12-11-2008
20090022791Porous cellulose aggregate and molding composition thereof - A porous cellulose aggregate characterized by having a secondary aggregate structure resulting from aggregation of primary cellulose particles, having a pore volume within a particle of 0.265 to 2.625 cm01-22-2009
20110256219Manufacturing Solid Pharmaceutical Dosage Forms With Visible Micro- And Nanostructured Surfaces And Micro- And Nanostructured Pharmaceutical Dosage Form - A solid pharmaceutical dosage form [10-20-2011
20120201881CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.08-09-2012
20080254119Imbedded liquid lubricants for tableting - The invention provides a nutritional supplement and/or pharmaceutical composition for tableting comprising an embedded lubrication matrix. The embedded lubrication matrix comprises an oily liquid finely dispersed in an oil insoluble material. A method of lubricating a nutritional supplement or pharmaceutical composition for tableting using a matrix with embedded lubrication is also provided.10-16-2008
20100285122TABLETS FOR COMBINATION THERAPY - The invention provides solid dose forms (e.g. tablets) comprising a compound of Formula I, a compound of Formula II, a compound of Formula III and a salt of Formula IV.11-11-2010
20100323006PHARMACEUTICAL SOLID PREPARATION COMPRISING BENZAZEPINES AND PRODUCTION METHOD THEREOF - The subject invention provides a novel pharmaceutical solid preparation that has superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients through the gastrointestinal tract. The pharmaceutical solid preparation of the present invention comprises: 12-23-2010
20100068269TREATMENT AND PREVENTION OF CARDIOVASCULAR EVENTS - A pharmaceutical dosage form for treating or preventing cardiovascular events comprises therapeutic amounts of: a β-adrenergic receptor antagonist, a diuretic, or both; a cholesterol-lowering agent; an inhibitor of the renin-angiotensin system; and aspirin.03-18-2010
20090186081Disintegrating Loadable Tablets - A disintegrating loadable tablet product in compressed form comprising i) at least 60% w/w of a sorbent material having a specific surface area (BET surface area) of at least 50 m2/g as measured by gas adsorption or mixtures of such sorbent materials, and ii) a disintegrant or a mixture of disintegrants wherein the tablet in compressed form has a) a porosity of 45% v/v or more, b) a hardness of at least 20 Newton, and c) a loading capacity of at least 30% of a liquid. The tablet is suitable for the preparation of a tablet containing an active substance by e.g. immersing the tablet in a liquid containing the active substance. The invention thus provides a safe and reproducible new method of preparing pharmaceutical tablets.07-23-2009
20100003318PROCESS FOR MAKING MULTIPARTICULATES USING A ROLLER COMPACTOR - A process for manufacturing multiparticulate pharmaceutical compositions using a roller compactor. The process is particularly useful for producing minitablets without the need of the use of a tablet press. The roller compactor features rolls having depressions or molds in the surface. Upon compaction of pharmaceutical blend, the minitablets are formed by the depressions in the roller surfaces.01-07-2010
20090202631METHODS AND DOSAGE FORMS FOR CONTROLLED DELIVERY OF PALIPERIDONE AND RISPERIDONE - Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.08-13-2009
20090175936Microtablet-Based Pharmaceutical Preparation - A pharmaceutical preparation consisting of various microtablets containing ingredients. The microtablets have the same form and the same weight.07-09-2009
20110189274Stable Pharmaceutical Compositions Of Montelukast Or Its Salts Or Solvates Or Hydrates - A stable pharmaceutical composition includes a therapeutically effective amount of montelukast or its pharmaceutically acceptable salts, solvates or hydrates and a blend which includes microcrystalline cellulose and a flavoring agent and wherein said composition is substantially free of montelukast sulfoxide degradation product. A process for preparing such composition is also disclosed.08-04-2011
20100021541Microparticulate form of a Tetrahydropyridine derivative - The invention relates to a microparticulate form of 1-[2-(2-naphthyl)-ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine hydrochloride consisting of particles for which at least 55% of the population have a diameter below 50 micrometers, and to pharmaceutical compositions in which it is present.01-28-2010
20090022792Vitamin D content uniformity in pharmaceutical dosage forms - New dosage forms of vitamin D and calcium carbonate having improved content uniformity are described. The improvements are realized through modifications to the formulation, the raw material specifications, and the process of manufacture.01-22-2009
20090274756Stabilized composition - It is intended to provide a pharmaceutical composition which contains a proton pump inhibitor and is stable even if it is stored for a long time. It is also intended to provide a pharmaceutical composition which contains a proton pump inhibitor susceptible to acid, and does not dissolve in the stomach but dissolves in the intestine to release a primary drug product promptly. The object could be achieved by the pharmaceutical composition characterized in that a layer containing a proton pump inhibitor and ethyl cellulose, a layer containing an enteric polymer, and if necessary an intermediate layer composed of one or more layers are formed on a pharmacologically inactive core substance. The intermediate layer is composed of a water-insoluble polymer, a water-soluble polymer, a lubricant and the like.11-05-2009
20090022793MESALAMINE SUPPOSITORY - The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 850 to about 1150 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 2250 to about 2700 mg. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40° C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.01-22-2009
20100062060PHARMACEUTICAL COMPOSITION COMPRISING TRAMADOL AND KETOPROFEN IN ASSOCIATION - The present invention relates to a pharmaceutical composition comprising a combination of active principles. More specifically: a stable pharmaceutical composition comprising a combination of tramadol and ketoprofen. Furthermore, a combination in solid form in which the active principles are vehicled in pharmaceutical forms and/or products that prevent contact between them. Complementarily, the present invention also relates to the combined use of ketoprofen and tramadol in the preparation of an oral medicine useful for relieving pain as well as a method for relieving pain with an oral pharmaceutical composition comprising a combination of tramadol and ketoprofen.03-11-2010
20080299190Direct Compression Formulation and Process - This invention relates to tablets especially tablets formed by direct compression of a dipeptidylpeptidase IV (DPP-IV) inhibitor compound, a process for the preparation thereof; to new pharmaceutical formulations, and new tableting powders comprising DPP-IV inhibitor formulations capable of being directly compressed into tablets. The invention relates further to a process for preparing the tablets by blending the active ingredient and specific excipients into the new formulations and then directly compressing the formulations into the direct compression tablets. The invention also relates to vildagliptin particle size distribution and a new crystal form of vildagliptin particularly adapted for the preparation of improved tablets and other pharmaceutical compositions.12-04-2008
20080317850Buccal Delivery System - A buccal delivery system capable of being blended in a normal dry powder process and compressed using a standard tabletting machine, said buccal delivery system comprising a matrix of: (a) an effective amount of one or more active ingredients; (b) an amount of one or more polyethylene glycols or derivatives thereof having a molecular weight between 1000 to 8000 sufficient to provide the required hardness and time for dissolution of the matrix; (c) 0.05-2% by weight of the total matrix of one or more suspending agents; (d) 0.05-2% by weight of the total matrix of one or more flowing agents; and (e) 0.05-2% by weight of the total matrix of one or more sweeteners.12-25-2008
20090130205Solid Pharmaceutical Composition Comprising Donepezil Hydrochloride - The invention relates to a solid pharmaceutical composition comprising donepezil hydrochloride hydrate and a process for its preparation. In particular it relates to a composition and a process wherein the donepezil hydrochloride retains its polymorphic form and is therefore highly stable against conversion into other polymorphic forms. 05-21-2009
20130011476STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN - Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.01-10-2013
20120301545CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.11-29-2012
20090081288Orodispersible Domperidone Tablets - The present invention relates to an orodispersible tablet comprised of, by weight: a maximum of 15% of a low-dose, therapeutically active substance; from 55% to 70% of mannitol of a particle size between 30 μm and 300 μm; at least 2% of maltodextrin; from 3.5% to 8% of croscarmellose sodium; from 10% to 20% of microcrystalline cellulose; from 0.5% to 1.5% of magnesium stearate; and from 1% to 5% of flavoring (s) and sweetener (s).03-26-2009
20090317460SOLID DOSAGE FORM - A solid dosage form comprises coated particles of bisphosphonate or a pharmaceutically acceptable analogue or derivative thereof.12-24-2009
20110064805Porous cellulose aggregate and molding composition thereof - A porous cellulose aggregate characterized by having a secondary aggregate structure resulting from aggregation of primary cellulose particles, having a pore volume within a particle of 0.265 to 2.625 cm03-17-2011
20110318411MULTI-LAYERED ORALLY DISINTEGRATING TABLET AND THE MANUFACTURE THEREOF - The present invention features a tablet containing a first layer and a second layer, wherein: (i) the first layer includes a pharmaceutically active agent and the composition of the first layer is different from the composition of the second layer; (ii) the tablet has a density less than about 0.8 g/cc; and (iii) the tablet disintegrates in the mouth when placed on the tongue in less than about 30 seconds.12-29-2011
20120207828LARGE DOSE RIBAVIRIN FORMULATIONS - The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg to 600 mg tablets. These dosage forms are bioequivalent to multiple doses of tablets containing small amounts of ribavirin.08-16-2012
20090317461ORAL COMPOSITIONS EFFECTIVE FOR THE TREATMENT OF ORAL CAVITY MALODOR ASSOCIATED WITH THE CONSUMPTION OF ODOR-CAUSING COMPOUNDS - This invention generally relates to oral compositions (e.g., a confection or chewing gum product) effective for the treatment of oral cavity malodor caused by odor-causing compounds (e.g., diallyl disulfide) associated with the consumption of, for example, garlic and/or onion. In particular, this invention relates to oral compositions containing menthone, isomenthone and, optionally, caryophyllene in varying concentrations, to provide an oral composition effective for the treatment of oral cavity malodor caused by odor-causing compounds associated with the consumption of, for example, garlic and onion.12-24-2009
20120003308Pharmaceutical Composition Comprising Aliskiren - The invention provides a pharmaceutical oral fixed dose combination of aliskiren and valsartan. It provides compressed bilayer tablets with both a high drug load and suitable physical properties, which can be produced using conventional equipment.01-05-2012
20090280171METHOD OF TREATMENT WITH PREDICTABLY BREAKABLE PHARMACEUTICAL TABLETS - The invention involves the use of finished dosage forms, e.g., tablets, by breaking or otherwise dividing them to produce a predictably accurate smaller or lower dose.11-12-2009
20120009257Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren - The invention provides a pharmaceutical oral fixed dose combination of aliskiren and valsartan. Aliskiren is shown to slow the dissolution rate of valsartan and the resultant undesirable gelling of valsartan in the presence of aliskiren is overcome by the use of disintegrants.01-12-2012
20120207830CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.08-16-2012
20120207829CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.08-16-2012
20120156292STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN - Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.06-21-2012
20120156291STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN - Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.06-21-2012
20110091544Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting - Small tablets for use in procedural sedation, anxiolysis and analgesia comprising the combination sufentanil and triazolam administered via the oral transmucosal route and methods for using the same are provided.04-21-2011
20120171286METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF STATIN-INDUCED MYOPATHY - Disclosed are methods for treating or preventing a statin-mediated myopathy in a subject via administration of a therapeutically effective amount of a geranylgeranylation activator. Further disclosed are kits containing a geranylgeranylation activator useful for the treatment of a statin-mediated myopathy.07-05-2012
20120315331PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE DISORDERS - A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.12-13-2012
20120315330PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE DISORDERS - A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.12-13-2012
20100247641MECHANICAL PROTECTIVE LAYER FOR SOLID DOSAGE FORMS - The present invention relates to a mechanical protective layer for pellets comprising at least two plasticizer agents, to a method for preparing the same and to a solid dosage form comprising the same.09-30-2010
20100136110GRANULAR PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION - A granular pharmaceutical composition for oral administration, wherein a drug-containing particle is coated with a coating comprising a methyl methacrylate-butyl methacrylate-dimethylaminoethyl methacrylate copolymer and a water-soluble polymer is disclosed.06-03-2010
20120164218SOLID DOSAGE FORMS OF VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE AND METHOD OF MAKING THE SAME - Monolayer, bilayer and trilayer solid dosage forms of a combination of valsartan, amlodipine and hydrochlorothiazide are made.06-28-2012
20120135075DOSAGE FORM - The present invention provides a dosage form, particularly a tamper resistant dosage form, comprising: melt-extruded particulates comprising a drug; and a matrix; wherein said melt-extruded particulates are present as a discontinuous phase in said matrix.05-31-2012
20120213849CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.08-23-2012
20100172978AQUEOUS COMPOSITION - Disclosed is an aqueous composition containing (a) an ethyl acrylate/methyl methacrylate copolymer or a plasticized vinyl accetate polymer, (b) an ethyl cellulose, (c) a water soluble additive for pharmaceutical products, (d) titanium oxide and (c) water. The solid content mass ratio among the components (a), (b), (c) and (d), namely a:b:c:d is 100:(5-50):(1-50):(0.5-10), and the solid content concentration in the aqueous composition is 0.5-40% by mass.07-08-2010
20120219621Composition with Enhanced Thermogenic Activity and the Use Thereof in the Prevention and Treatment of Obesity - A composition with enhanced thermogenic activity and the use thereof in the prevention and treatment of obesity08-30-2012
20120076856ORODISPERSIBLE PHARMACEUTICAL COMPOSITION OF PERINDOPRIL - The invention relates to a solid orodispersible pharmaceutical composition of perindopril, characterised in that it comprises perindopril or a pharmaceutically acceptable salt thereof and granules consisting of co-dried lactose and starch.03-29-2012
20120177733SOLID DOSAGE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD OF MAKING THE SAME - Monolayer and bilayer solid dosage forms of a combination of valsartan and amlodipine are made.07-12-2012
20100008986PHARMACEUTICAL COMPOSITIONS COMPRISING SUMATRIPTAN AND NAPROXEN - The present invention relates to the pharmaceutical composition comprising sumatriptan succinate and naproxen sodium, with a proviso that both the active components are in admixture with each other.01-14-2010
20100008985DOSAGE UNIT FOR SUBLINGUAL, BUCCAL OR ORAL ADMINISTRATION OF WATER-INSOLUBLE PHARMACEUTICALLY ACTIVE SUBSTANCES - One aspect of the invention relates to a pharmaceutical dosage unit for sublingual, buccal, pulmonary or oral administration, said dosage unit having a weight of 20-500 mg and comprising 1-80 Wt. % of a microgranulate that is distributed throughout a solid hydrophilic matrix; said microgranulate being characterised in that it: has a volume weighted average diameter of 5-100 m; contains at least 0.01 wt. %, preferably at least 0.1 wt. % of one or more water-insoluble pharmaceutically active substances; contains at least 10 wt. %, preferably at least 20 wt. % of an emulsifier component; and is capable of forming a micro-emulsion upon contact with saliva or water. The dosage units of the present invention achieve the inherent benefits of oral delivery whilst at the same time realising a high transmucosal absorption rate of the cannabinoids contained therein. Other aspects of the present invention relate to the use of the aforementioned dosage units in the therapeutic or prophylactic treatment and to a process for the manufacture of said dosage units.01-14-2010
20100008984Solid dispersions comprising tacrolimus - A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.01-14-2010
20120225121BIOEQUIVALENT FORMULATION OF EFAVIRENZ - The present invention provides a suitable technique namely wet milling and the process for reducing the particle size of efavirenz and making a tablet or capsule formulation with desired bioavailability equivalent to the reference listed drug without loosing its characteristics.09-06-2012
20110123616Calcium Carbonate Granulation - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.05-26-2011
20110123615SOLID PHARMACEUTICAL COMPOSITION - The present invention relates to a solid preparation containing a compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof, a pH control agent and a diuretic, which is superior in the stability and dissolution property of the compound represented by the formula (I) and the diuretic.05-26-2011
20120231075ABUSE-RESISTANT OPIOID DOSAGE FORM - We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.09-13-2012
20090148520TABLET - The present invention can inhibit the occurrence of defective products without increasing the hardness of a tablet even if stress is applied to the tablet on transporting it or packing it by an automatic dispensing machine or when taking it out of the PTP and besides can be put into practice easily and inexpensively to result in facilitating the improvement of the productivity. A tablet according to the present invention comprises a body portion (06-11-2009
20130011475STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN - Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.01-10-2013
20090004266Nanoparticles for protein drug delivery - The invention discloses a chewable composition for oral delivery of bioactive agents having nanoparticles that are composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular protein drug and bioactive agent delivery.01-01-2009
20130011473Preparation Method Of The Solid Formulation Of Clopidogrel Bisulfate - A solid formulation of clopidogrel bisulfate and its preparation method are disclosed. The formulation comprises clopidogrel bisulfate as active ingredient, colloidal silicon dioxide as anti-adherent/coating and the carriers selected from diluent, binder, glidant, disintegrant and/or lubricant.01-10-2013
20130011474MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE - The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing memantine that exhibit an enhanced release profile and provide reliable absorption. The dosage forms may be used to treat mild, moderate or severe Alzheimer's disease or neuropathic pain.01-10-2013
20080254118PROCESS FOR PREPARING PRAMIPEXOLE DIHYDROCHLORIDE TABLETS - The present invention relates to a process for preparing tablets of pramipexole dihydrochloride. In particular, the present invention relates to a process for preparing tablets of pramipexole dihydrochloride wherein the tablets exhibit enhanced storage stability properties.10-16-2008
20080254117PROCESS FOR PREPARING PRAMIPEXOLE DIHYDROCHLORIDE TABLETS - The present invention relates to a process for preparing tablets of pramipexole dihydrochloride. In particular, the present invention relates to a process for preparing tablets of pramipexole dihydrochloride wherein the tablets exhibit enhanced storage stability properties.10-16-2008
20080213359Calcium sulfate based nanoparticles - The present invention provides a method for facilitating repair of an area of bone by providing hemihydrate calcium sulfate particles, mixing the particles with an aqueous solution to obtain a paste, applying the paste to an area of bone in need of repair, and allowing the paste to set.09-04-2008
20130095180TIME-DELAYED SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION COMPRISING DAPOXETINE FOR ORAL ADMINISTRATION - The present invention relates to a time-delayed sustained release pharmaceutical composition for oral administration, which comprises an immediate release phase and a prolonged sustained release phase, wherein said immediate release phase and prolonged sustained release phase respectively comprise Dapoxetine therein as an active ingredient. The pharmaceutical composition of the present invention comprises Dapoxetine, which is an agent for treating premature ejaculation, in both the immediate release phase and the prolonged sustained release phase thereof, to thereby immediately exhibit the effectiveness of the pharmaceutical composition of the present invention in order to enable a patient to achieve sexual satisfaction during the early stage of administration, as well as to reduce side effects by means of the time-delayed sustained release of the prolonged sustained release phase during the early stage of administration and enable a continuous in vivo absorption of Dapoxetines, to thereby lengthen the duration of the effectiveness of the pharmaceutical composition of the present invention. Further, agents for treating erectile dysfunction, such as sildenafil, tadalifil or the like can be added to the immediate release phase so as to allow for a coincidence of the durations of the effectiveness of a premature ejaculation treatment agent and erectile dysfunction treatment agents, even though a half-life difference exists between the two types of treatment agents, thus maximizing patient satisfaction.04-18-2013
20130115287INTRAORALLY DISINTEGRATING TABLET - Disclosed is an orally disintegrating tablet which masks bitterness, dissolves well, and which permanently retains good oral disintegration properties immediately following manufacture. The disclosed orally disintegrating tablet is formed by compression-molding an organic acid together with particles comprising active ingredient-containing nuclear particles covered by a layer containing water-insoluble polymers and/or enteric polymers.05-09-2013
20130101670FORMULATIONS COMPRISING COATED FINE PARTICLES - [OBJECT] To provide an intraorally rapidly disintegrating tablet comprising 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid as an active ingredient, which is a formulation that causes virtually no irritating sensation in the oral cavity or pharynx, and retains good dissolution and oral disintegration properties even when it is stored under high temperature/high humidity conditions.04-25-2013
20110212171TASTE MASKED TOPIRAMATE COMPOSITION AND AN ORALLY DISINTEGRATING TABLET COMPRISING THE SAME - In various embodiments, the present invention is directed to a taste masked pharmaceutical composition comprising a therapeutically effective amount of taste masked sulfamate-substituted monosaccharide particles comprising a sulfamate-substituted monosaccharide or a pharmaceutically acceptable salt or derivative thereof that are coated with one or more taste-masking layers, and optionally one or more of taste-masked neltrexone, 5-HT09-01-2011
20080199520S-Adenosyl-L-Methionine for Regulating Behavioral Disorders in Pets - The present invention relates to the use of S-adenosyl-L-methionine or its salts for preparing a composition for the regulation of behavioral problems in pets.08-21-2008
20120276198PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE AND PREPARATION METHOD THEREOF - A pharmaceutical composition used to treat Parkinson's disease contains levodopa, carbidopa and entacapone or pharmaceutically acceptable salt thereof, and at least one kind of pharmaceutically acceptable excipients. Entacapone is not mixed with levodopa or carbidopa in the pharmaceutical composition. The preparation method of the pharmaceutical composition includes making the first particles with levodopa and carbidopa, making the second particles with entacapone, and then pressing the two kinds of particles into tablets.11-01-2012
20120258170PHARMACEUTICAL CO-CRYSTALS OF QUERCETIN - A co-crystal composition comprised of Quercetin and at least one antidiabetic agent acts as a combination drug having unique physical properties and biological activity, which differ from both Quercetin in pure form and the at least one antidiabetic agent in pure form. The co-crystal composition may comprise quercetin and metformin. The co-crystals of quercetin and metformin may be prepared by grinding the compounds, and used in pharmaceutical compositions comprising these co-crystals. Co-crystal compositions of quercetin and Metformin may be used in combination with other anti-diabetic agents, including DPP-IV inhibitors.10-11-2012
20130189357Methods and Delivery Vehicles for Providing Throat Relief - Methods and delivery vehicles are provided for providing throat relief.07-25-2013
20130209557TAMPER RESISTANT DOSAGE FORM COMPRISING INORGANIC SALT - The invention relates to a pharmaceutical dosage form exhibiting a breaking strength of at least 500 N, said dosage form containing a pharmacologically active ingredient (A); an inorganic salt (B); and a polyalkylene oxide (C) having a weight average molecular weight of at least 200,000 g/mol, wherein the content of the polyalkylene oxide (C) is at least 20 wt.-%, based on the total weight of the dosage form; wherein the pharmacologically active ingredient (A) is present in a controlled-release matrix comprising the inorganic salt (B) and the polyalkylene oxide (C) and wherein, under in vitro conditions, the release profile of the pharmacologically active ingredient (A) from said matrix comprises at least a time interval during which the release follows zero order kinetics.08-15-2013

Patent applications in class Tablets, lozenges, or pills

Patent applications in all subclasses Tablets, lozenges, or pills